Elliot Stieglitz, MD
|School||UCSF School of Medicine|
|Address||550 16th Street|
San Francisco CA 94143
|UCSF||2014||St. Baldrick's Foundation Fellowship|
Juvenile myelomonocytic leukemia (JMML) is a type of blood cancer that affects children and is very difficult to treat. Currently available treatments cure only half of the patients, with some children experiencing aggressive courses while others get better with very little treatment.
My first objective is to identify biomarkers associated with a poor prognosis in order to establish a risk stratification algorithm that will prevent using toxic chemotherapy in patients who are predicted not to respond. I am using several next generation sequencing techniques in order to identify these biomarkers including exome sequencing, DNA methylation analysis and droplet digital PCR. Second, with specific biomarkers in place, I can identify targeted medications that would be predicted to improve outcomes for these patients.
People in Profiles who have published with this person.